XORTX Therapeutics Inc.
XRTX.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 9.50% | -2.72% | -670.37% | 120.87% | -445.09% |
| Total Depreciation and Amortization | 6.52% | 6.15% | -0.38% | 0.77% | -21.52% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 61.31% | 28.87% | 68.80% | -208.24% | 84.52% |
| Change in Net Operating Assets | -14.89% | -75.35% | 198.05% | -580.07% | -91.40% |
| Cash from Operations | 20.66% | -23.27% | 27.38% | -17.89% | -2.09% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 74.77% | -541.18% | 15.00% | 82.76% | -154.95% |
| Cash from Investing | 74.77% | -541.18% | 15.00% | 82.76% | -154.95% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 8.15% | -0.87% | -1.76% | -2.25% | -149.44% |
| Issuance of Common Stock | -- | -100.00% | -92.43% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1,123.76% | 11.40% | 93.84% | -- | -- |
| Cash from Financing | 1,876.27% | -164.20% | -93.89% | 5,086.49% | -149.44% |
| Foreign Exchange rate Adjustments | -119.63% | 2,354.55% | 102.52% | -324.10% | 880.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 115.68% | -43.81% | -434.53% | 122.23% | -2.73% |